13. 多発性硬化症／視神経脊髄炎 Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details
臨床試験数 : 3,342 / 薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04940065 (ClinicalTrials.gov) | June 30, 2021 | 22/6/2021 | Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen | Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen (Relapsing-remitting Multiple Sclerosis and Active Secondary Progressive Multiple Sclerosis) | Relapsing-remitting Multiple Sclerosis;Active Secondary Progressive Multiple Sclerosis | Other: Kesimpta | Novartis Pharmaceuticals | NULL | Recruiting | N/A | 99 Years | All | 330 | Japan |